Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Multicentre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozinin Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2

Next Previous
X
Search
Trial Profile

A Phase 2b Multicentre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozinin Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary) ; Zibotentan (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Acronyms ZENITH-CKD
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 03 Nov 2023 Primary endpoint has been met. (Change in Log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline to Week 12), as per Results published in the Lancet
    • 03 Nov 2023 Results published in the Lancet
    • 03 Nov 2023 According to an AstraZeneca media release, results were presented today at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top